InsiderTrades.com logo
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>

ALZN Insider Trading

Insider Ownership Percentage: 10.55%
Insider Buying (Last 12 Months): $16,784.80
Insider Selling (Last 12 Months): $0.00

Alzamend Neuro Insider Trading History Chart

This chart shows the insider buying and selling history at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Share Price & Price History

Current Price: $3.81
Price Change: ▼ Price Decrease of -0.08 (-2.06%)
As of 07/26/2024 01:00 AM ET

This chart shows the closing price history over time for ALZN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.

Alzamend Neuro Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2024Milton C. Ault IIIDirectorBuy100$6.90$690.0077,169View SEC Filing Icon  
4/1/2024Milton C. Ault IIIDirectorBuy33$9.10$300.3077,069View SEC Filing Icon  
1/5/2024Milton C. Ault IIIDirectorBuy500$10.20$5,100.0076,836View SEC Filing Icon  
12/26/2023Milton C. Ault IIIMajor ShareholderBuy50$9.00$450.002,603View SEC Filing Icon  
12/22/2023Milton C. Ault IIIMajor ShareholderBuy20$9.20$184.0016,686View SEC Filing Icon  
9/26/2023David J KatzoffCFOBuy353$28.50$10,060.50540View SEC Filing Icon  
5/24/2023Milton C. Ault IIIMajor ShareholderBuy120$88.50$10,620.002,553View SEC Filing Icon  
4/28/2023Stephan JackmanCEOBuy246$81.00$19,926.00303View SEC Filing Icon  
3/22/2023Lynne Fahey McgrathDirectorBuy66$64.50$4,257.0066View SEC Filing Icon  
3/16/2023Milton C. Ault IIIMajor ShareholderBuy26$75.00$1,950.0073,700View SEC Filing Icon  
2/15/2023Milton C. Ault IIIMajor ShareholderBuy6$90.00$540.0073,673View SEC Filing Icon  
12/27/2022Milton C. Ault IIIMajor ShareholderBuy6$88.50$531.0073,646View SEC Filing Icon  
11/18/2022Milton C. Ault IIIMajor ShareholderBuy6$193.50$1,161.0073,586View SEC Filing Icon  
10/31/2022Milton C. Ault IIIMajor ShareholderBuy40$178.50$7,140.0067,351View SEC Filing Icon  
10/12/2022Milton C. Ault IIIMajor ShareholderBuy13$184.50$2,398.5067,311View SEC Filing Icon  
10/6/2022Milton C. Ault IIIMajor ShareholderBuy6$214.50$1,287.0067,297View SEC Filing Icon  
9/29/2022Milton C. Ault IIIMajor ShareholderBuy23$178.50$4,105.5067,291View SEC Filing Icon  
9/19/2022Stephan JackmanCEOBuy56$184.50$10,332.0056View SEC Filing Icon  
9/14/2022David J KatzoffCFOBuy66$166.50$10,989.00186View SEC Filing Icon  
8/25/2022Milton C. Ault IIIMajor ShareholderBuy32$144.00$4,608.0066,717View SEC Filing Icon  
8/22/2022Milton C. Ault IIIMajor ShareholderBuy240$145.50$34,920.0066,684View SEC Filing Icon  
8/15/2022Milton C. Ault IIIMajor ShareholderBuy93$159.00$14,787.0066,344View SEC Filing Icon  
8/3/2022Milton C. Ault IIIMajor ShareholderBuy13$142.50$1,852.5066,244View SEC Filing Icon  
7/27/2022Milton C. Ault IIIMajor ShareholderBuy38$130.50$4,959.0066,231View SEC Filing Icon  
7/22/2022Milton C. Ault IIIMajor ShareholderBuy15$136.50$2,047.5066,193View SEC Filing Icon  
7/18/2022Milton C. Ault IIIMajor ShareholderBuy66$147.00$9,702.0066,177View SEC Filing Icon  
6/29/2022Milton C. Ault IIIMajor ShareholderBuy66$132.00$8,712.0066,111View SEC Filing Icon  
6/17/2022Milton C. Ault IIIMajor ShareholderBuy66$132.00$8,712.0066,044View SEC Filing Icon  
6/14/2022Milton C. Ault IIIMajor ShareholderBuy66$127.50$8,415.0065,911View SEC Filing Icon  
6/7/2022Milton C. Ault IIIMajor ShareholderBuy13$141.00$1,833.0065,791View SEC Filing Icon  
6/2/2022Milton C. Ault IIIMajor ShareholderBuy53$144.00$7,632.0065,777View SEC Filing Icon  
5/26/2022Milton C. Ault IIIMajor ShareholderBuy66$136.50$9,009.0065,644View SEC Filing Icon  
5/24/2022Milton C. Ault IIIMajor ShareholderBuy107$133.50$14,284.5065,577View SEC Filing Icon  
5/17/2022Milton C. Ault IIIMajor ShareholderBuy159$147.00$23,373.0065,437View SEC Filing Icon  
5/12/2022Milton C. Ault IIIMajor ShareholderBuy166$127.50$21,165.0065,277View SEC Filing Icon  
5/5/2022Milton C. Ault IIIMajor ShareholderBuy666$160.50$106,893.002,166View SEC Filing Icon  
4/26/2022Milton C. Ault IIIMajor ShareholderBuy17,777$225.00$3,999,825.0064,444View SEC Filing Icon  
4/22/2022Milton C. Ault IIIMajor ShareholderBuy500$141.00$70,500.001,500View SEC Filing Icon  
4/11/2022Milton C. Ault IIIMajor ShareholderBuy333$169.50$56,443.501,000View SEC Filing Icon  
3/31/2022Mark GustafsonDirectorSell133$181.50$24,139.50400View SEC Filing Icon  
3/18/2022Milton C. Ault IIIMajor ShareholderBuy666$165.00$109,890.00View SEC Filing Icon  
2/24/2022Milton C. Ault IIIMajor ShareholderBuy150$172.50$25,875.00View SEC Filing Icon  
1/27/2022Milton C. Ault IIIMajor ShareholderBuy16$210.00$3,360.00View SEC Filing Icon  
1/24/2022Milton C. Ault IIIMajor ShareholderBuy33$193.50$6,385.50View SEC Filing Icon  
1/18/2022Milton C. Ault IIIMajor ShareholderBuy46$249.00$11,454.00View SEC Filing Icon  
1/14/2022Milton C. Ault IIIMajor ShareholderBuy20$268.50$5,370.00View SEC Filing Icon  
1/7/2022Milton C. Ault IIIMajor ShareholderBuy20$289.50$5,790.00View SEC Filing Icon  
1/5/2022Milton C. Ault IIIMajor ShareholderBuy13$297.00$3,861.00View SEC Filing Icon  
12/23/2021Milton C. Ault IIIMajor ShareholderBuy10$315.00$3,150.00View SEC Filing Icon  
12/20/2021Milton C. Ault IIIMajor ShareholderBuy166$316.50$52,539.00View SEC Filing Icon  
12/17/2021Milton C. Ault IIIMajor ShareholderBuy86$372.00$31,992.00View SEC Filing Icon  
12/14/2021Mark GustafsonDirectorSell133$427.50$56,857.50View SEC Filing Icon  
11/30/2021Milton C. Ault IIIMajor ShareholderBuy35$340.50$11,917.50View SEC Filing Icon  
11/22/2021Milton C. Ault IIIMajor ShareholderBuy100$285.00$28,500.00View SEC Filing Icon  
11/8/2021Milton C. Ault IIIMajor ShareholderBuy966$385.50$372,393.00View SEC Filing Icon  
9/14/2021Milton C. Ault IIIMajor ShareholderBuy33$405.00$13,365.001,000View SEC Filing Icon  
8/27/2021Milton C. Ault IIIMajor ShareholderBuy40$435.00$17,400.00View SEC Filing Icon  
8/17/2021Milton C. Ault IIIMajor ShareholderBuy26$493.50$12,831.00View SEC Filing Icon  
8/12/2021Milton C. Ault IIIMajor ShareholderBuy22$580.50$12,771.00View SEC Filing Icon  
8/9/2021Milton C. Ault IIIMajor ShareholderBuy3$607.50$1,822.50View SEC Filing Icon  
8/6/2021Milton C. Ault IIIMajor ShareholderBuy26$610.50$15,873.00View SEC Filing Icon  
8/4/2021Milton C. Ault IIIMajor ShareholderBuy3$645.00$1,935.00View SEC Filing Icon  
8/2/2021Milton C. Ault IIIMajor ShareholderBuy10$684.00$6,840.00View SEC Filing Icon  
7/30/2021Milton C. Ault IIIMajor ShareholderBuy8,922$226.50$2,020,833.00View SEC Filing Icon  
7/26/2021Milton C. Ault IIIMajor ShareholderBuy23$741.00$17,043.00View SEC Filing Icon  
7/23/2021Milton C. Ault IIIMajor ShareholderBuy33$864.00$28,512.00View SEC Filing Icon  
See Full Table
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.

SEC Filings (Institutional Ownership Changes) for Alzamend Neuro (NASDAQ:ALZN)

49.61% of Alzamend Neuro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALZN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alzamend Neuro Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/20/2024Virtu Financial LLC26,482$26K0.0%N/A0.385%Search for SEC Filing on Google Icon
2/2/2024Truist Financial Corp154,327$0.14M0.0%-93.3%2.168%Search for SEC Filing on Google Icon
5/11/2022RFG Advisory LLC250,000$0.31M0.0%N/A0.277%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087%Search for SEC Filing on Google Icon
4/22/2022Truist Financial Corp2,314,907$2.85M0.0%N/A2.569%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC116,666$0.22M0.0%N/A0.131%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP172,913$0.53M0.0%N/A0.199%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC14,000$43K0.0%N/A0.016%Search for SEC Filing on Google Icon
11/15/2021Sassicaia Capital Advisers LLC93,762$0.29M0.8%N/A0.108%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC15,402$0.14M0.0%N/A0.018%Search for SEC Filing on Google Icon
8/16/2021Cubist Systematic Strategies LLC23,672$0.21M0.0%N/A0.028%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC44,600$0.39M0.0%N/A0.052%Search for SEC Filing on Google Icon
8/11/2021Susquehanna International Group LLP57,030$0.50M0.0%N/A0.067%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More on Alzamend Neuro

Today's Range

Now: $3.81
Low: $3.62
High: $4.16

50 Day Range

MA: $4.69
Low: $3.52
High: $6.39

52 Week Range

Now: $3.81
Low: $3.27
High: $73.41

Volume

26,595 shs

Average Volume

8,253 shs

Market Capitalization

$30.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Who are the company insiders with the largest holdings of Alzamend Neuro?

Alzamend Neuro's top insider shareholders include:
  1. Milton C Ault III (Director)
  2. Milton C Ault III (Major Shareholder)
  3. David J Katzoff (CFO)
  4. Stephan Jackman (CEO)
  5. Lynne Fahey Mcgrath (Director)
Learn More about top insider investors at Alzamend Neuro.

Who are the major institutional investors of Alzamend Neuro?

Alzamend Neuro's top institutional shareholders include:
  1. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Alzamend Neuro stock.
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>